RxDoctor Payments Data

Jessie Alperin, MD

Rheumatology · Warren, MINPI 1447697164

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,075 of the $21,322 with a category attached, or 70.7%. Lilly USA, LLC accounts for 87.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $12,778 and has fallen 95.6% since, to $561 in 2025.

$21,322in general payments, 2019–2025

Across 155 payments — averaging $137.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$19K
  • Amgen$843
  • Johnson & Johnson$472
  • UCB, Inc.$262
  • Novartis$183
  • Pfizer$153
  • plus $697 from 10 others

What the payments were for

  • Consulting fees$1,8008%
  • Speaking & faculty fees$15,07571%
  • Travel & lodging$1,4687%
  • Food & beverage$2,84813%
  • Education$1301%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,322 in reported general payments places this provider in the 80th percentile of 195 rheumatology providers in Michigan.

See all rheumatology providers in Michigan

Medicare billing

Part B allowed, 2024
$825,241
Medicare patients
186
Services billed
53,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab49$430,404
Enbrel SureclickEtanercept36$261,920
Orencia ClickjectAbatacept29$182,938
RinvoqUpadacitinib21$155,797
Cosentyx Sensoready (2 Pens)Secukinumab14$105,058
Taltz SyringeIxekizumab13$90,458
OtezlaApremilast13$63,556
Actemra ActpenTocilizumab13$59,746
MethotrexateMethotrexate Sodium358$13,474
Hydroxychloroquine Sulfate174$9,302
LyricaPregabalin11$6,555
Leflunomide72$5,287
Pregabalin24$1,885
Prednisone196$1,877
Allopurinol107$1,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$113$155,79721 claims
AmgenOtezla$843$63,55613 claims
PfizerLyrica$153$6,55511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 195 rheumatology providers in Michigan.

Other rheumatology in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →